Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate

被引：0
|
作者：
Ezziddin, S. [1 ]
Sabet, A. [1 ]
Heinemann, F. [1 ]
Yong-Hing, C. [2 ]
Ahmadzadehfar, H. [1 ]
Guhlke, S. [1 ]
Hoeller, T. [1 ]
Willinek, W. [1 ]
Boy, C. [3 ]
Biersack, H. [1 ]
机构：
[1] Univ Hosp, Bonn, Germany
[2] Univ British Columbia Hosp, Vancouver, BC, Canada
[3] Univ Hosp, Essen, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S139 / S139
页数：1
相关论文
共 50 条
  • [41] Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
    Flavio Forrer
    Eric P. Krenning
    Peter P. Kooij
    Bert F. Bernard
    Mark Konijnenberg
    Willem H. Bakker
    Jaap J. M. Teunissen
    Marion de Jong
    Kirsten van Lom
    Wouter W. de Herder
    Dik J. Kwekkeboom
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36
  • [42] Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
    Forrer, Flavio
    Krenning, Eric P.
    Kooij, Peter P.
    Bernard, Bert F.
    Konijnenberg, Mark
    Bakker, Willem H.
    Teunissen, Jaap J. M.
    de Jong, Marion
    van Lom, Kirsten
    de Herder, Wouter W.
    Kwekkeboom, Dik J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (07) : 1138 - 1146
  • [43] Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
    Kashyap, Raghava
    Hofman, Michael S.
    Michael, Michael
    Kong, Grace
    Akhurst, Timothy
    Eu, Peter
    Zannino, Diana
    Hicks, Rodney J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) : 176 - 185
  • [44] Combination of peptide receptor radionuclide therapy (PRRT) using 177Lu-octreotate and RAD001, further investigations on metastasis and tumour response in a rat pancreatic cancer model
    Bison, S. M.
    Pool, S.
    Koelewijn, S. J.
    Groen, H. C.
    Melis, M.
    de Jong, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S326 - S326
  • [45] Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
    Raghava Kashyap
    Michael S. Hofman
    Michael Michael
    Grace Kong
    Timothy Akhurst
    Peter Eu
    Diana Zannino
    Rodney J. Hicks
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 176 - 185
  • [46] Simplification of absorbed dose calculation to the bone marrow in patients receiving 177Lu-Octreotate therapy
    Sandstrom, Mattias
    Ilan, Ezgi
    Lindskog, Karolina
    Sundin, Anders
    Lubberink, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [47] irtGPUMCD: a new GPU-calculated dosimetry code for 177Lu-octreotate radionuclide therapy of neuroendocrine tumors
    Montegiani, Jean-Francois
    Gaudin, Emilie
    Jackson, Price A.
    Beauregard, Jean-Mathieu
    Despres, Philippe
    MEDICAL PHYSICS, 2014, 41 (08) : 1 - 1
  • [48] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: preliminary dosimetry, efficacy and safety results from the P-PRRT trial
    Del Prete, M.
    Arsenault, F.
    Saighi, N.
    Bouchard, L. O.
    Beaulieu, A.
    Buteau, F. A.
    Beauregard, J. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S60 - S61
  • [49] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [50] Does dosimetry predict the haematological toxicity after Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Tyr3-octreotate?
    Konijnenberg, M. W.
    Krenning, E. P.
    Cock, J. Boesen-De
    Erion, J. L.
    Kooij, P. P. M.
    Kwekkeboom, D. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S280 - S281
12345